Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 20 | 2023 | 1118 | 2.600 |
Why?
|
| Insulin Resistance | 2 | 2022 | 392 | 0.650 |
Why?
|
| Biopsy, Needle | 3 | 2002 | 132 | 0.480 |
Why?
|
| Mammary Glands, Human | 4 | 2019 | 53 | 0.460 |
Why?
|
| Breast | 4 | 2007 | 173 | 0.450 |
Why?
|
| Physician Incentive Plans | 1 | 2013 | 9 | 0.440 |
Why?
|
| Weight Gain | 2 | 2022 | 163 | 0.430 |
Why?
|
| Medical Oncology | 1 | 2013 | 57 | 0.420 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 44 | 0.420 |
Why?
|
| Quality of Health Care | 1 | 2013 | 513 | 0.320 |
Why?
|
| Female | 22 | 2023 | 30719 | 0.300 |
Why?
|
| Mastectomy | 3 | 2022 | 52 | 0.290 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2023 | 75 | 0.280 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2005 | 45 | 0.240 |
Why?
|
| Humans | 25 | 2023 | 59366 | 0.230 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2004 | 29 | 0.230 |
Why?
|
| Carcinoma, Lobular | 1 | 2004 | 23 | 0.220 |
Why?
|
| Neoplasms, Second Primary | 1 | 2004 | 43 | 0.220 |
Why?
|
| Carcinoma in Situ | 1 | 2004 | 32 | 0.220 |
Why?
|
| Estrogens | 2 | 2023 | 109 | 0.210 |
Why?
|
| Intraoperative Period | 1 | 2003 | 33 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 71 | 0.200 |
Why?
|
| Middle Aged | 14 | 2023 | 16310 | 0.200 |
Why?
|
| Postmenopause | 2 | 2023 | 224 | 0.200 |
Why?
|
| Body Mass Index | 2 | 2022 | 831 | 0.200 |
Why?
|
| Biopsy | 2 | 2007 | 410 | 0.200 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2022 | 15 | 0.200 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2022 | 39 | 0.190 |
Why?
|
| Papilloma | 1 | 2002 | 12 | 0.190 |
Why?
|
| Mastectomy, Segmental | 1 | 2022 | 45 | 0.190 |
Why?
|
| Insulin | 2 | 2022 | 673 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 300 | 0.170 |
Why?
|
| Patient Care Team | 1 | 2023 | 327 | 0.170 |
Why?
|
| Mammography | 1 | 2022 | 269 | 0.160 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 461 | 0.160 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 124 | 0.160 |
Why?
|
| Epithelial Cells | 2 | 2022 | 391 | 0.160 |
Why?
|
| Cancer Survivors | 1 | 2020 | 79 | 0.160 |
Why?
|
| Prospective Studies | 2 | 2022 | 3067 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 152 | 0.150 |
Why?
|
| Benzhydryl Compounds | 1 | 2018 | 48 | 0.150 |
Why?
|
| Phenols | 1 | 2018 | 74 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 474 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 402 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 84 | 0.130 |
Why?
|
| Transcriptome | 1 | 2019 | 340 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 515 | 0.120 |
Why?
|
| Regression Analysis | 2 | 2007 | 486 | 0.120 |
Why?
|
| Energy Metabolism | 1 | 2017 | 359 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 588 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 718 | 0.110 |
Why?
|
| Adult | 10 | 2020 | 15679 | 0.110 |
Why?
|
| Reimbursement, Incentive | 1 | 2013 | 28 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2019 | 850 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 902 | 0.110 |
Why?
|
| Stereotaxic Techniques | 2 | 2007 | 29 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 29 | 0.100 |
Why?
|
| Exercise | 1 | 2020 | 883 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6069 | 0.100 |
Why?
|
| Parity | 1 | 2013 | 70 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 1552 | 0.100 |
Why?
|
| Risk Factors | 4 | 2020 | 4986 | 0.100 |
Why?
|
| Cell Lineage | 1 | 2013 | 259 | 0.090 |
Why?
|
| Norovirus | 1 | 2011 | 6 | 0.090 |
Why?
|
| Virus Shedding | 1 | 2011 | 19 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2013 | 337 | 0.090 |
Why?
|
| Breast Diseases | 1 | 2011 | 39 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 39 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2011 | 68 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 82 | 0.090 |
Why?
|
| Diarrhea | 1 | 2011 | 75 | 0.090 |
Why?
|
| Stem Cells | 1 | 2013 | 255 | 0.090 |
Why?
|
| Disease Progression | 3 | 2023 | 1119 | 0.090 |
Why?
|
| Ultrasonography | 2 | 2003 | 457 | 0.080 |
Why?
|
| Aged | 7 | 2020 | 13405 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2013 | 417 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 450 | 0.070 |
Why?
|
| Therapeutic Touch | 1 | 2007 | 2 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1479 | 0.060 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2005 | 8 | 0.060 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2005 | 16 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 31 | 0.060 |
Why?
|
| Pain Management | 1 | 2007 | 146 | 0.060 |
Why?
|
| United States | 2 | 2013 | 7426 | 0.060 |
Why?
|
| Pain | 1 | 2007 | 396 | 0.060 |
Why?
|
| Cyclohexanols | 1 | 2004 | 17 | 0.060 |
Why?
|
| Oxygen | 1 | 2005 | 313 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2023 | 21 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 1189 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2023 | 30 | 0.050 |
Why?
|
| Perioperative Care | 1 | 2004 | 76 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2005 | 5119 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 448 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 323 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2004 | 141 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2022 | 12 | 0.050 |
Why?
|
| Estradiol | 1 | 2023 | 247 | 0.050 |
Why?
|
| Vacuum | 1 | 2002 | 7 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2002 | 29 | 0.050 |
Why?
|
| Equipment Design | 1 | 2003 | 329 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2020 | 5281 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 628 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2020 | 96 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 414 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 1999 | 40 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 121 | 0.040 |
Why?
|
| Histological Techniques | 1 | 1999 | 18 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2516 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2020 | 99 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 1999 | 76 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 84 | 0.040 |
Why?
|
| Apoptosis | 2 | 2020 | 1032 | 0.040 |
Why?
|
| Obesity | 1 | 2007 | 1166 | 0.040 |
Why?
|
| Cytodiagnosis | 1 | 1999 | 44 | 0.040 |
Why?
|
| Gene Expression | 1 | 2022 | 809 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4273 | 0.040 |
Why?
|
| Calcinosis | 1 | 1999 | 79 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 1559 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 147 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 225 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 141 | 0.040 |
Why?
|
| Credentialing | 1 | 1997 | 15 | 0.040 |
Why?
|
| Pyruvic Acid | 1 | 2017 | 13 | 0.040 |
Why?
|
| Cell Respiration | 1 | 2017 | 21 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 49 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 1997 | 92 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 302 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 1999 | 1027 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 1091 | 0.030 |
Why?
|
| Data Collection | 1 | 1997 | 371 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2018 | 283 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 941 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1597 | 0.030 |
Why?
|
| General Surgery | 1 | 1997 | 191 | 0.030 |
Why?
|
| Pain Measurement | 2 | 2007 | 327 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 1997 | 0.030 |
Why?
|
| Massachusetts | 1 | 2020 | 2019 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1306 | 0.030 |
Why?
|
| Radiology | 1 | 1997 | 236 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 1137 | 0.030 |
Why?
|
| Stomatitis | 1 | 2013 | 7 | 0.030 |
Why?
|
| Capecitabine | 1 | 2013 | 10 | 0.030 |
Why?
|
| Niacinamide | 1 | 2013 | 32 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 30 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2013 | 40 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2013 | 55 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2013 | 49 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2013 | 57 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 228 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 284 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 103 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2053 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2013 | 76 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1997 | 692 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 396 | 0.020 |
Why?
|
| Gynecomastia | 1 | 2011 | 11 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 805 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 715 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 116 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 217 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2011 | 101 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3615 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 5835 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 2903 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 365 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 1078 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2007 | 136 | 0.020 |
Why?
|
| Human papillomavirus 6 | 1 | 2005 | 4 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2005 | 15 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 36 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 10294 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 2213 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2005 | 132 | 0.020 |
Why?
|
| Oncogenes | 1 | 2005 | 66 | 0.020 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2004 | 15 | 0.010 |
Why?
|
| Anxiety | 1 | 2007 | 387 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 675 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 170 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 847 | 0.010 |
Why?
|
| Analgesics | 1 | 2004 | 96 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 19649 | 0.010 |
Why?
|
| Male | 2 | 2011 | 27742 | 0.010 |
Why?
|